Opus Genetics公司近日宣布，其基因治疗候选药物Opgx-Lca5已获得美国食品药品监督管理局（FDA）批准，正式纳入罕见病证据原则（Rdep）计划。这一重要进展标志着该公司在针对罕见遗传性视网膜疾病治疗领域的研发迈出关键一步。
罕见病证据原则计划旨在加速针对罕见疾病的创新疗法开发，通过提供更灵活的监管路径和证据标准，帮助像Opus Genetics这样的生物技术公司更高效地推进临床试验和上市申请。Opgx-Lca5作为针对LCA5基因突变相关莱伯先天性黑蒙症的治疗方案，此次入选将进一步推动该药物的临床开发进程。
对于Opus Genetics而言，此次FDA的认可不仅验证了其科学平台的技术潜力，也为后续与其他监管机构的沟通奠定了坚实基础。公司表示将充分利用这一计划提供的支持，加速为患有罕见视网膜疾病的患者提供创新治疗方案。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.